探讨细胞周期检测点激酶1（Chk1）在肝细胞癌（肝癌）中的表达及其对肝癌侵袭能力的影响。

标本来源于2005年6月至2010年6月在广州医科大学附属肿瘤医院行根治性肝切除术的127例患者的肝癌及癌旁组织。所有患者均签署知情同意书，符合医学伦理学规定。其中男116例，女11例；年龄23～77岁，中位年龄50岁。采用免疫组织化学方法检测肝癌和癌旁组织中Chk1表达，并分别采用Huh7和MHCC-97H肝癌细胞进行Transwell细胞侵袭实验。实验分为两组，Chk1抑制剂组（抑制组）加入Chk1小分子抑制剂G?6976，对照组加入0.1%二甲基亚砜（DMSO）。观察肝癌和癌旁组织中Chk1的表达情况，以及Chk1表达与临床病理学参数的关系。两组穿膜细胞数比较采用t检验，率的比较采用χ²检验。

肝癌组织Chk1阳性率为80.3% （102/127），明显高于癌旁肝组织的15.0%（19/127） （χ²=108.700，P<0.05）。肿瘤数目多发、无肿瘤包膜、术后早期复发的患者肝癌组织中Chk1高表达（χ²= 6.289，4.713，5.039；P<0.05）。抑制剂组Huh7和MHCC-97H肝癌细胞的穿膜细胞数分别为（127±8）、（136±10）个，对照组相应为（174±11）、（188±13）个，抑制组明显低于对照组（t =-3.402，-3.136；P<0.05）。

肝癌组织中存在Chk1高表达，Chk1高表达与肝癌的侵袭和转移有关，Chk1抑制剂可有效抑制肝癌细胞的侵袭能力。

To investigate the expression of cell cycle checkpoint kinase 1 (Chk1) and its impact on the invasion capacity of hepatocellular carcinoma (HCC).

Samples of HCC tissues and adjacent non-tumor tissues from 127 patients undergoing radical hepatectomy in Cancer Center of Guangzhou Medical University from June 2005 to June 2010 were collected. The informed consents of all patients were obtained and the ethical committee approval was received. The patients included 116 males and 11 females with age ranging from 23 to 77 years old and a median age of 50 years old. The expression of Chk1 was detected by immunohistochemistry, and Transwell cell invasion assay was performed using HCC cells Huh7 and MHCC-97H. The experiment was divided into two groups. Chk1 small-molecule inhibitor G?6976 was added in Chk1 inhibitor group (inhibitor group). Dimethyl sulfoxide (DMSO, 0.1%) was added in control group. The expression of Chk1 in HCC tissues and adjacent non-tumor tissues, the relation between Chk1 expression and clinicopathological indicators were observed. The difference of cell-membrane penetrating count in two groups was compared using t test. The comparison of rates was conducted using Chi-square test.

The positive rate of Chk1 in HCC tissues [80.3% (102/127)] was significantly higher than that in adjacent non-tumor tissues [15.0% (19/127)] (χ²=108.700, P<0.05). High expression of Chk1 was observed in HCC tissues of patients with multiple tumors, non-coating tumors or early tumor recurrence after operation (χ²= 6.289, 4.713, 5.039; P<0.05). The cell-membrane penetrating counts of HCC cells Huh7 and MHCC-97H in inhibitor group (127±8, 136±10) were significantly lower than those in control group (174±11, 188±13) ( t =-3.402, -3.136; P<0.05).

High expression of Chk1 can be observed in HCC tissues. It’s associated with the invasion and metastasis of HCC. The Chk1 inhibitor can effectively suppress the invasion capacity of HCC cells.